NEW YORK, April 19 (Reuters) - Amgen Inc.'s. anemia drug Aranesp showed no increased risk of death compared to a placebo in a study of small-cell lung cancer patients undergoing chemotherapy, sending ...

Early results from a novel treatment strategy for chemotherapy-related anemia: Epoetin alfa 60,000 U SC QW induction followed by 60,000 U SC Q2W Conclusions: Epoetin alfa was safe and well tolerated ...

April 23, 2007 — Using actual US practice patterns and dosing, epoetin alfa (Epogen; peg-EPO therapy) effectively maintains hemoglobin (Hb) levels in hemodialysis patients, according to a presentation ...

After a stroke, uric acid therapy reduces disability in women. Epoetin dose is significantly associated with cardiovascular disease whether patients had lower or higher hemoglobin levels, study finds.

BARCELONA, Sept 26 (Reuters) - New data suggests that extended doses of Amgen's best-selling anaemia drug Aranesp, when paired with chemotherapy treatment, work as well as weekly doses, the company ...

Breast cancer patients (N = 354) receiving chemotherapy were randomly assigned in 1:1 ratio to epoetin alfa (40,000 U qw) or standard of care (SOC). QOL was assessed at baseline and week 12.

Amgen Inc.’s anemia treatment Aranesp is safe for use in kidney patients whose disease doesn’t require dialysis, a U.S. panel said Monday. Outside advisers to the Food and Drug Administration said the ...